Get the latest news, insights, and market updates on MRVL (Marvell Technology, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Marvell Pursues Data Center Growth With Celestial AI And XConn Deals
Marvell Technology (NasdaqGS:MRVL) has agreed to acquire Celestial AI and XConn Technologies to expand its data center product lineup. The deals focus on optical photonic fabric and PCIe/CXL switching, aimed at strengthening Marvell's position in next generation data center infrastructure. Management has outlined ambitious growth targets for the acquired businesses as they are integrated into Marvell's broader data center strategy. For investors watching Marvell at a share price of $79.09,... Feb 19, 2026 - $MRVL
AXT (AXTI) Reports Q4 Loss, Misses Revenue Estimates
AXT (AXTI) delivered earnings and revenue surprises of -15.47% and -10.14%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock? Feb 19, 2026 - $MRVL
Is Marvell (MRVL) a Buy as Wall Street Analysts Look Optimistic?
The average brokerage recommendation (ABR) for Marvell (MRVL) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock? Feb 18, 2026 - $MRVL
Marvel Biosciences Secures Funding to Develop Child-Friendly Liquid Formulation for Neurodevelopmental Disorders
Calgary, Alberta--(Newsfile Corp. - February 18, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), is pleased to announce that it is receiving advisory services and funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support research and development of a pediatric-friendly liquid formulation of its lead compound, MB-204.The NRC IRAP-supported project will focus on creating a small-volume oral liquid formulation designed for... Feb 18, 2026 - $MRVL
Marvel Biosciences Announces Grant of Deferred Share Units
Calgary, Alberta--(Newsfile Corp. - February 18, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announces the award of 50,001 deferred share units ("DSUs") to Marvel's three independent directors, in lieu of cash payment for directors' fees.The DSUs will all vest on February 17, 2027. Vested DSUs shall be settled upon the directors' separation from service from the Company and expire 365 days... Feb 18, 2026 - $MRVL
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple